CN121490025A

CN121490025A - Traditional Chinese medicine composition for treating atrophic gastritis and preparation method thereof

Info

Publication number: CN121490025A
Application number: CN202311380610.4A
Authority: CN
Inventors: 胡东辉
Original assignee: Individual
Current assignee: Individual
Priority date: 2023-10-24
Filing date: 2023-10-24
Publication date: 2026-02-10

Abstract

本发明公开一种治疗萎缩性胃炎的中药组合物及其制备方法，所述的治疗萎缩性胃炎的中药组合物，由以下重量份的原料制备而成：当归 3‑10、川芎 3‑10、白芍 10‑30、蒲公英 5‑20、墨莲草 10‑30、半枝莲 5‑20、荔枝核 5‑20、枳壳 5‑20、百合 10‑30、厚朴 5‑20、天花粉 5‑20、茵陈10‑30、鸡内金 3‑10、白花蛇舌草 10‑30、金银花10‑30、甘草2‑10。本发明中药组合物能够较好的治疗治疗萎缩性胃炎，效果显著，安全可靠。This invention discloses a traditional Chinese medicine composition for treating atrophic gastritis and its preparation method. The traditional Chinese medicine composition for treating atrophic gastritis is prepared from the following raw materials in parts by weight: Angelica sinensis 3-10, Ligusticum chuanxiong 3-10, Paeonia lactiflora 10-30, Taraxacum mongolicum 5-20, Eclipta prostrata 10-30, Scutellaria barbata 5-20, Litchi chinensis seed 5-20, Citrus aurantium 5-20, Lilium brownii 10-30, Magnolia officinalis 5-20, Trichosanthes kirilowii 5-20, Artemisia capillaris 10-30, Gallus gallus domesticus gizzard lining 3-10, Hedyotis diffusa 10-30, Lonicera japonica 10-30, and Glycyrrhiza uralensis 2-10. The traditional Chinese medicine composition of this invention can effectively treat atrophic gastritis, with significant efficacy and reliable safety.

Description

Traditional Chinese medicine composition for treating atrophic gastritis and preparation method thereof

Technical Field

The application relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating atrophic gastritis and a preparation method thereof.

Background

Chronic atrophic gastritis is also known as atrophic gastritis. Refers to the pathological changes of the common thickening of mucosal muscular layer, which are caused by the atrophy and even disappearance of the mucosa intrinsic glands after the gastric mucosal surface is repeatedly damaged. Gastric mucosa becomes thinner to varying degrees due to glandular atrophy or disappearance, and is often accompanied by intestinal metaplasia, inflammatory reactions and atypical hyperplasia.

Chronic atrophic gastritis is characterized by a prolonged illness and long-term dyspepsia. The traditional Chinese medicine mainly shows abdominal distension, is more obvious when people eat more, is tasteless and tasteless, is dull and painful in the gastric cavity, is tired, is emaciated, is poor in appetite, and is characterized in that the pathogenesis causes of chronic atrophic gastritis in the categories of 'distention and fullness', 'epigastralgia', and the like in the traditional Chinese medicine are not completely elucidated until now, and are generally considered to be related to the influences of immune factors, bile reflux, biological factors, drug factors and related diseases, and are considered to be related to emotional disorder, improper diet, weakness of the spleen and the stomach, congenital deficiency, and the like. In the treatment of the disease, the traditional Chinese medicine and the western medicine are both special therapeutic drugs and methods, and the traditional Chinese medicine mainly starts from the whole and treats according to the principle of dialectical treatment. In recent years, the traditional Chinese medicine has a lot of reports on treating chronic atrophic gastritis, has a good prescription, and is helpful for improving subjective symptoms and promoting recovery of patients. Chronic atrophic gastritis has long disease course and slow progress, and complications such as gastrorrhagia, gastric ulcer, anemia, gastric cancer and the like often appear in the pathological changes process, and the chronic atrophic gastritis should be considered to be important for medical workers and patients.

The etiology and pathogenesis of chronic atrophic gastritis are not well understood. It is considered that chronic atrophic gastritis is formed by chronic inflammation of gastric mucosa, repeated damage to gastric mucosal surface, atrophy of gastric secretion glands, discoloration of gastric mucosa, thinning, blood vessel exposure, gastric acid secretion reduction, reduced digestive function, gastric peristalsis and the like caused by immune factors, bile reflux, biological factors, drug factors, acute gastritis, oral and nasopharyngeal infections and the like, as well as emotional disorders, improper diet, excessive fatigue, insomnia, catching cold and the like.

Traditional Chinese medicine considers spleen and stomach weakness and qi stagnation as basic pathological mechanism of chronic atrophic gastritis. The senile yin deficiency, internal injury of seven emotions, food stagnation of phlegm and blood stasis caused by chronic diseases can cause the spleen and stomach to be damaged, the ascending and descending are weak, the qi movement is not smooth, and symptoms such as distention and fullness of the gastric cavity, dull pain, anorexia, hypodynamia and the like are presented. The disease belongs to the symptoms of deficiency, excess and cold and heat, takes the deficiency of the body resistance as the root, causes the pathogenic factors to be more concentrated when the body resistance is deficient, causes the pathogenic factors to be more deficient when the pathogenic factors are concentrated, and often affects each other, so that the disease is difficult to heal quickly. The research and development of a traditional Chinese medicine for treating atrophic gastritis, which has more definite curative effect and is safe and reliable, has important significance.

Disclosure of Invention

The invention provides a traditional Chinese medicine composition for treating atrophic gastritis and a preparation method thereof, and the traditional Chinese medicine composition can be used for better treating atrophic gastritis, and has the advantages of remarkable effect, safety and reliability.

In order to achieve the above purpose, the technical scheme of the invention is as follows:

the traditional Chinese medicine composition for treating atrophic gastritis is prepared from the following raw materials in parts by weight:

3-10 parts of angelica sinensis, 3-10 parts of ligusticum wallichii, 10-30 parts of white paeony root, 10-40 parts of dandelion, 10-30 parts of eclipta alba, 5-20 parts of barbed skullcap herb, 5-20 parts of lychee seed, 5-20 parts of fructus aurantii, 10-30 parts of lily, 5-20 parts of magnolia officinalis, 5-20 parts of radix trichosanthis, 10-30 parts of capillary artemisia, 3-10 parts of endothelium corneum gigeriae galli, 10-30 parts of oldenlandia diffusa, 10-30 parts of honeysuckle and 2-10 parts of liquorice.

Preferably, the feed is prepared from the following raw materials in parts by weight:

4-8 parts of Chinese angelica, 4-8 parts of szechuan lovage rhizome, 15-25 parts of white paeony root, 10-30 parts of dandelion, 10-20 parts of common flowery knotweed herb, 8-16 parts of barbed skullcap herb, 5-15 parts of lychee seed, 8-16 parts of bitter orange, 20-30 parts of lily, 5-15 parts of magnolia officinalis, 8-16 parts of mongolian snakegourd root, 8-16 parts of virgate wormwood herb, 4-8 parts of chicken's gizzard-skin, 15-25 parts of oldenlandia diffusa, 10-20 parts of honeysuckle and 4-8 parts of liquorice.

Preferably, the active ingredient is prepared by water extraction or ethanol extraction with the volume percentage concentration of 40-80%.

Preferably, the preparation method of the active ingredient comprises the following steps:

adding water 8-12 times of the total weight of all the medicinal materials, decocting for 1-3 times, each for 1-2 hr, mixing the extractive solutions, filtering, and concentrating under reduced pressure to obtain soft extract.

Mixing all the above materials, reflux-extracting with 40-80% ethanol for 2-3 times, each time with ethanol amount of 4-10 times of total amount of the materials for 1-3 hr, mixing extractive solutions, filtering, and concentrating the filtrate into soft extract to obtain active ingredient.

Preferably, the preparation method of the concentrated pill comprises the following steps:

drying the active ingredients at 60-80deg.C, pulverizing into fine powder with 80-120 mesh sieve, adding Mel and water, making into 2-3mm pill, and drying at 60-80deg.C.

The invention also provides a traditional Chinese medicine preparation for treating atrophic gastritis, which is applied to the traditional Chinese medicine composition for treating atrophic gastritis and a pharmaceutically acceptable carrier.

Pharmaceutically acceptable carriers of the invention include, but are not limited to, the following:

diluents such as zinc oxide, calamine, starch, powdered sugar, lactose, dextrin, microcrystalline cellulose, inorganic salts, sugar alcohols, etc.

The binder is gelatin, polyethylene glycol, cellulose derivative, adeps ragmitis, vaseline, silicone oil, lanoline, cellulose, gum, raw rubber, lead soap, lanoline, etc.

Organic solvents such as boric acid, lead acetate, copper sulfate, zinc sulfate, aluminum acetate, rivanol, furacilin, neomycin, potassium permanganate, diethyl ether, ethanol, acetone, etc.

Disintegrating agents such as starch, sodium carboxymethyl starch, cellulose derivatives, crospovidone, etc.

The lubricant comprises magnesium stearate, silica gel micropowder, talcum powder, polyethylene glycol, triethanolamine, sodium laurylsulfate, stearic acid, cetyl alcohol, polyethylene glycol, monoglyceride, span, tween, etc.

Emulsifying agent such as adeps ragmitis, vaseline, silicone oil, lanoline, polyethylene glycol, cellulose, etc.

Cosolvent such as water, ethanol, glycerol, propylene glycol, liquid paraffin, vegetable oil, dimethyl sulfoxide, azelastone, etc.

Flavoring agent such as sucrose, monosaccharide, and aromatic.

Preservative such as benzoic acid, sorbic acid, methyl ester, ethyl ester, propyl ester, etc.

The preparation method of each traditional Chinese medicine preparation formulation comprises the following steps:

1. Powder:

the active ingredients of the traditional Chinese medicine composition for treating atrophic gastritis are dried and crushed to obtain powder;

2. tablet:

the active ingredients of the traditional Chinese medicine composition for treating atrophic gastritis are dried, crushed and pressed into tablets.

3. The capsule comprises the following components:

The active ingredients of the traditional Chinese medicine composition for treating atrophic gastritis are dried, crushed and then filled into hollow capsules or sealed into elastic soft capsules to obtain capsules, wherein the materials for forming the hollow hard capsule shell or the elastic soft capsule shell are gelatin, glycerol, water and other medicinal materials.

4. The granule comprises the following components:

the active ingredients of the traditional Chinese medicine composition for treating atrophic gastritis are dried, crushed, mixed with proper auxiliary materials and granulated to obtain granules, wherein the auxiliary materials comprise diluents, absorbents, wetting agents, adhesives, flavoring agents and effervescent auxiliary materials.

5. Solutions or suspensions:

The active ingredients of the traditional Chinese medicine composition for treating atrophic gastritis are dissolved in water, vegetable oil or other medicinal liquid solvents to obtain a solution or a suspension.

The prescription of the invention is as follows, and the pathogenesis of atrophic gastritis is considered to be caused by liver and spleen imbalance, damp-heat toxin entering collaterals to damage stomach yin, and qi and blood stasis. Herba Artemisiae Scopariae, radix Paeoniae alba, radix Angelicae sinensis, rhizoma Ligustici Chuanxiong with effects of promoting blood circulation, softening liver and removing blood stasis as monarch, fructus Aurantii, cortex Magnolia officinalis, semen litchi, endothelium corneum Gigeriae Galli with effects of regulating qi-flowing, invigorating spleen, eliminating turbid pathogen as ministerial drugs, herba Taraxaci, herba Hedyotidis Diffusae, herba Scutellariae Barbatae with effects of clearing heat, detoxicating and resisting cancer as adjuvant drugs, bulbus Lilii, glycyrrhrizae radix with effects of regulating qi and blood, tranquilizing mind, regulating stomach, moistening dryness of Trichosanthis radix, preventing intestinal epithelium, nourishing yin and clearing heat as messenger drugs. The medicines are combined, so that the gastric mucosa gland atrophy and intestinal epithelial metaplasia can be reversed, and the tumor is resisted.

The traditional Chinese medicine composition is summarized on the basis of a large number of clinical experimental researches, accords with the traditional Chinese medicine theory and the modern medical theory, has no toxic or side effect, complements each other among the traditional Chinese medicines, and has good curative effect on atrophic gastritis.

Detailed Description

The present invention will be described in detail with reference to the following examples.

Example 1

3kg of angelica sinensis, 3kg of ligusticum wallichii, 10kg of white paeony root, 10kg of dandelion, 10kg of common flowery knotweed herb, 5kg of barbed skullcap herb, 5kg of lychee seed, 5kg of fructus aurantii, 10kg of lily, 5kg of magnolia officinalis, 5kg of radix trichosanthis, 10kg of capillary artemisia, 3kg of chicken's gizzard-membrane, 10kg of oldenlandia diffusa, 10kg of honeysuckle and 2kg of liquorice.

The preparation method of the active ingredients comprises the following steps:

Adding water 8 times of the total weight of all the medicinal materials, decocting for 1 time and 1 hr each time, mixing the extractive solutions, filtering, and concentrating under reduced pressure to obtain soft extract with relative density of 1.20 at 80deg.C.

The preparation method of the concentrated pill comprises the following steps:

Drying the active ingredients at 60deg.C, pulverizing into fine powder, sieving with 80 mesh sieve, adding refined Mel and water, making into pill, making into 2mm pill, and drying at 60-deg.C.

Example 2

10kg of angelica sinensis, 10kg of ligusticum wallichii, 30kg of white paeony root, 40kg of dandelion, 30kg of common flowery knotweed herb, 20kg of barbed skullcap herb, 20kg of lychee seed, 20kg of fructus aurantii, 30kg of lily, 20kg of magnolia officinalis, 20kg of radix trichosanthis, 30kg of capillary artemisia, 10kg of chicken's gizzard-membrane, 30kg of oldenlandia diffusa, 30kg of honeysuckle and 10kg of liquorice.

The preparation method of the active ingredients comprises the following steps:

Adding water 12 times of the total weight of all the medicinal materials, decocting for 3 times and 2 hours each time, mixing the extractive solutions, filtering, concentrating under reduced pressure to obtain soft extract with relative density of 1.30 at 80deg.C, and obtaining the active ingredient.

The preparation method of the concentrated pill comprises the following steps:

Drying the active ingredients at 80deg.C, pulverizing into fine powder, sieving with 120 mesh sieve, adding Mel and water, making into pill, and drying at 80deg.C.

Example 3

6kg of angelica sinensis, 6kg of ligusticum wallichii, 15kg of white paeony root, 18kg of dandelion, 15kg of common flowery knotweed herb, 12kg of barbed skullcap herb, 12kg of lychee seed, 12kg of fructus aurantii, 25kg of lily, 10kg of magnolia officinalis, 12kg of radix trichosanthis, 12kg of capillary artemisia, 6kg of chicken's gizzard-membrane, 18kg of oldenlandia diffusa, 12kg of honeysuckle and 6kg of liquorice.

The preparation method of the active ingredient comprises the following steps:

Adding water 10 times of the total weight of all the medicinal materials, decocting for 2 times and 1.5 hr each time, mixing extractive solutions, filtering, and concentrating under reduced pressure to obtain soft extract.

The preparation method of the concentrated pill comprises the following steps:

Drying the active ingredients at 70deg.C, pulverizing into fine powder, sieving with 100 mesh sieve, adding Mel and water, making into pill, making into 2.5mm pill, and drying at 70deg.C.

Example 4

4kg of angelica sinensis, 4kg of ligusticum wallichii, 15kg of white paeony root, 15kg of dandelion, 10kg of common flowery knotweed herb, 8kg of barbed skullcap herb, 5kg of lychee seed, 5kg of fructus aurantii, 10kg of lily, 5kg of magnolia officinalis, 8kg of radix trichosanthis, 10kg of capillary artemisia, 4kg of chicken's gizzard-membrane, 15kg of oldenlandia diffusa, 10kg of honeysuckle and 4kg of liquorice.

The preparation method of the active ingredient comprises the following steps:

mixing all the medicinal materials, reflux-extracting with 45% ethanol for 2 times, wherein the ethanol consumption is 6 times of the total amount of the medicinal materials, extracting for 2 hr, mixing the extractive solutions, filtering, and concentrating under reduced pressure to obtain soft extract with relative density of 1.23 at 80deg.C to obtain active ingredient.

The traditional Chinese medicine composition of the embodiment is prepared into tablets, and the preparation method comprises the following steps:

And (3) drying the active ingredients, crushing, mixing with a proper amount of starch and dextrin, sieving with a 100-mesh sieve, and tabletting to obtain the tablet.

Example 5

8kg of angelica sinensis, 8kg of ligusticum wallichii, 25kg of white paeony root, 15kg of dandelion, 20kg of common flowery knotweed herb, 16kg of barbed skullcap herb, 15kg of lychee seed, 15kg of fructus aurantii, 20kg of lily, 15kg of magnolia officinalis, 16kg of radix trichosanthis, 20kg of capillary artemisia, 8kg of chicken's gizzard-membrane, 25kg of oldenlandia diffusa, 13kg of honeysuckle and 7kg of liquorice.

The preparation method of the active ingredient comprises the following steps:

adding water 9 times of the total weight of all the medicinal materials, decocting for 2 times each for 1.3 hr, mixing extractive solutions, filtering, and concentrating under reduced pressure to obtain soft extract with relative density of 1.26 at 80deg.C.

The traditional Chinese medicine composition of the embodiment is prepared into capsules, and the preparation method comprises the following steps:

and (3) drying the active ingredients, crushing, sieving with an 80-mesh sieve, and filling into hollow capsules to obtain capsules.

Example 6

6kg of angelica sinensis, 7kg of ligusticum wallichii, 16kg of white paeony root, 28kg of dandelion, 12kg of common flowery knotweed herb, 12kg of barbed skullcap herb, 11kg of lychee seed, 16kg of fructus aurantii, 16kg of lily, 8kg of magnolia officinalis, 8kg of radix trichosanthis, 18kg of capillary artemisia, 7kg of chicken's gizzard-membrane, 22kg of oldenlandia diffusa, 18kg of honeysuckle and 4kg of liquorice.

The preparation method of the active ingredient comprises the following steps:

Adding water 11 times of the total weight of all the medicinal materials, decocting for 2 times each for 1.6 hr, mixing extractive solutions, filtering, and concentrating under reduced pressure to obtain soft extract with relative density of 1.24 at 80deg.C.

The traditional Chinese medicine composition of the embodiment is prepared into granules, and the preparation method comprises the following steps:

mixing the active ingredients with proper amount of starch and sugar powder, granulating, and drying to obtain granule.

Experimental example 1 summary of clinical trials

1. The case selection is to take 100 cases of chronic atrophic gastritis patients, namely, patients treated by department of medical inpatient in third people's hospital in Hubei province in 2021, 3 months and 2023 months. All cases were randomized into 2 groups at a 1:1 ratio, 50 observations, ages 39-66, mean 56.16 + -7.35, 50 controls, ages 41-65, mean 55.78 + -8.17. No other major systemic diseases are found in the examination, and the two groups of ages, pathogenesis reasons, physical conditions and the like have no significant difference (P > 0.05) and are comparable.

2. Diagnostic criteria:

Reference is made to "chinese chronic gastritis consensus" (2017 edition )[Jiang J X,Liu Q,Mao X Y,et al.Downward trend in the prevalence of Helicobacter pyloriinfections and corresponding frequent upper gastrointestinal diseases profile changes in Southeastern China between 2003and 2012[J].Springerplus,2016,5(1):1601.] is in compliance with the diagnostic criteria for chronic atrophic gastritis:

the endoscope diagnosis standard is that the white and red phases of mucous membrane are seen under the endoscope, the white phases are mainly used, folds flatten or even disappear, mucous membrane blood vessels are exposed, and mucous membrane particles or nodules and the like are basically expressed.

Pathological histological diagnosis standard, that is, the pathological biopsy shows the inherent gland atrophy, namely, the atrophic gastritis can be diagnosed.

3. Criteria for Chinese medical symptoms:

referring to "chronic atrophic gastritis Combined diagnosis and treatment consensus opinion" [ Li Junxiang, chen, lv Bin, wang Yangang. Chronic atrophic gastritis combined diagnosis and treatment consensus opinion (2017) [ J ]. Chinese, western and Chinese combined journal of digestion, 2018,26 (02): 121-131 ] ], new Chinese medicine clinical study guidelines [ Zhengyu ]. New Chinese medicine clinical study guidelines [ M ]. Beijing: chinese medical science and technology publishing, 2002:125-128 ],

The main symptoms are epigastric pain and epigastric fullness and oppression.

The secondary symptoms include anorexia, (2) belching, singultus, (3) acid regurgitation or heartburn, (4) chest distress, chest pain, (5) loose stool, and (6) listlessness.

4. Symptom score:

The main symptoms include gastric fullness and gastralgia, each of which is not obvious according to subjective severity, 0 point in the product, 2 points in the product, obvious symptoms but not affecting life and work, 4 points in the product, heavy symptoms, the need of medicine control, 6 points in the product, and 0-7 points in the product according to days of attack per week.

The secondary syndrome is that each term has no integral of 0 point and some integral of 2 points.

The total is divided into the sum of the principal syndrome score and the secondary syndrome score.

5. Treatment effect score for syndromes:

calculated by nimodipine scoring method, therapeutic index (%) = (integral before treatment-

Post-treatment integral)/pre-treatment integral x 100%.

① Healing, wherein the curative effect index is more than or equal to 95%;

② The obvious effect is that the curative effect index is less than or equal to 70 percent and less than 95 percent;

③ The effective rate is 30 percent or less, and the curative effect index is less than 70 percent;

④ The efficacy index is less than 30%.

6. Treatment group:

The Chinese medicinal composition comprises 6g of Chinese angelica, 6g of szechuan lovage rhizome, 15g of white paeony root, 18g of dandelion, 15g of common flowery knotweed herb, 12g of barbed skullcap herb, 12g of lychee seed, 12g of bitter orange, 25g of lily, 10g of magnolia bark, 12g of mongolian snakegourd root, 12g of virgate wormwood herb, 6g of chicken's gizzard-skin, 18g of oldenlandia diffusa, 12g of honeysuckle flower and 6g of liquorice. Decocting with water twice, mixing decoctions, concentrating to 300ml, and taking twice daily in the morning and evening for 4 weeks as a treatment course, and evaluating the curative effect after administration.

7. Control group:

The Moruodan is orally taken 1 bag at a time and 3 times a day. The specification was 1.84 g/bag. According to the guidelines of clinical research of new Chinese medicine, the common consensus opinion of the Chinese medical science and medical expert of chronic gastritis (2017 edition) [ Zhang Shengsheng, tang Xudong, huang Suiping, liqun ], the common consensus opinion of the Chinese medical science and medical expert of chronic gastritis (2017) [ J ]. J.Chinese medicine, 2017,32 (07): 3060-3064 ], the treatment course is 4 weeks, and the curative effect is evaluated after the administration is finished.

8. Experimental conditions:

1. Chinese medicine symptom integral comparison before and after two groups of treatments

The main symptoms are that the degree, frequency and total integral are significantly reduced (P < 0.05) after 1 week of administration of the observation group and the treatment group compared with the prior administration. The observed and treated groups were significantly reduced in degree, frequency and total integral after 4 weeks of dosing compared to 1 week of dosing (P < 0.05), and there was no statistical difference in degree, frequency and total integral of the main symptoms after 4 weeks of dosing (P > 0.05) between the observed and treated groups prior to 1 week of dosing. See table 1.

TABLE 1 integral of primary symptoms before and after administration for each group of patients

Note that ΔP <0.05 compared to pre-dose and bar P <0.05 compared to 1 week of dose

2. Integration of symptoms before and after administration for each group of patients

The secondary symptoms are that the secondary symptoms have no obvious difference (P > 0.05) in the integral of the secondary symptoms after the administration of the observation group and the control group for 1 week compared with the administration before the administration, and the integral of the secondary symptoms has obviously decreased (P < 0.05) in the observation group and the secondary symptoms after the administration for 4 weeks compared with the administration for 1 week. The group comparison, the observation group and the treatment group have no obvious difference (P > 0.05) between the integral and the total integral of each secondary symptoms before administration, and the observation group has better total integral than the control group (P < 0.05) and no obvious difference (P > 0.05) after administration for 1 week compared with the control group. After 4 weeks of administration, the observed group had belch, acid regurgitation and heartburn, chest distress and chest pain integral and the total integral of secondary symptoms were superior to the control group (P < 0.05) with no obvious difference (P > 0.05) compared with the control group. See table 2.

TABLE 2 integration of symptoms before and after administration for each group of patients

Note that Δp <0.05 compared to pre-dose in this group and P <0.05 compared to control group

3. Total score before and after dosing for each group of patients:

The total integral of the observed group and the control group was not significantly different (P > 0.05) before the administration for 1 week compared with the group, and significantly decreased (P < 0.05) after the administration for 4 weeks compared with the control group. See table 3.

TABLE 3 total integral of symptoms before and after administration for each group of patients

Note that compared to the control group, P <0.05

4. Comparison of clinical efficacy of two groups of treatments

The nimodipine method calculates the curative effect index to evaluate the total integral, the observed group is higher than the control group in cure rate, the obvious effect is equivalent to that of the control group, and the observed group is better than the control group (P < 0.05) in the overall syndrome evaluation. See table 4.

Table 4 evaluation of the efficacy index of each group of patients (%, n)

While the invention has been described in detail in the foregoing general description, embodiments and experiments, it will be apparent to those skilled in the art that modifications and improvements can be made thereto. Accordingly, such modifications or improvements may be made without departing from the spirit of the invention and are intended to be within the scope of the invention as claimed.

Claims

1. The traditional Chinese medicine composition for treating atrophic gastritis is characterized by being prepared from the following raw materials in parts by weight:

2. The traditional Chinese medicine composition for treating atrophic gastritis according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight:

3. The Chinese medicinal composition for treating atrophic gastritis according to claim 1 or 2, wherein the active ingredient is prepared by water extraction or ethanol extraction with a concentration of 40-80% by volume.

4. The Chinese medicinal composition for treating atrophic gastritis according to claim 3, wherein the preparation method of the active ingredients comprises the following steps:

5. The Chinese medicinal composition for treating atrophic gastritis as claimed in claim 3, wherein the preparation method of the active ingredients comprises the following steps:

6. The Chinese medicinal composition for treating atrophic gastritis according to claim 3, wherein the preparation method of the concentrated pill comprises the following steps:

7. A Chinese medicinal preparation for treating atrophic gastritis, which uses the Chinese medicinal composition for treating atrophic gastritis as claimed in any one of claims 1-6 and a pharmaceutically acceptable carrier.